Contrast-induced nephropathy (CIN) refers to acute kidney injury occurring after exposure to iodinated contrast media used in imaging studies and interventional procedures. Patients with pre-existing kidney disease, diabetes, dehydration, or advanced age are at increased risk. IMH places strong emphasis on prevention, early detection, and prompt management of CIN.

Preventive strategies begin with risk stratification before contrast exposure. Nephrologists and radiologists collaborate to assess kidney function, review comorbidities, and determine the necessity of contrast use. When possible, alternative imaging modalities are considered.

Hydration remains the cornerstone of CIN prevention. IMH follows standardized hydration protocols using isotonic fluids before and after contrast administration, tailored to patient cardiovascular status. Nephrotoxic medications are temporarily withheld when appropriate.

Post-procedure monitoring includes serial kidney function tests and urine output assessment. Early detection allows timely intervention, minimizing progression to severe AKI.
Treatment of CIN focuses on supportive care, optimization of fluid balance, electrolyte correction, and avoidance of further nephrotoxic exposure. In severe cases, renal replacement therapy may be required.

Through proactive prevention and coordinated care, IMH significantly reduces the incidence and severity of contrast-related kidney injury.